Abstract
Proper bone development requires the coordinated and calibrated action of various cells, hormones, enzymes and nutrients. In this paper, we present two clinical cases of metabolic bone disorders – one with excessive fibroblast growth factor-23 (FGF23) and the other, with low alkaline phosphatase. FGF23 and alkaline phosphatase are not-so-well-known players in bone health. This paper puts the spotlight on these two, and discusses their role in bone development, and how abnormal levels lead to disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
